Below is a case report I recently received from Stefan, a visitor of this website. The case report is related to his sister-in-law, a 74-years lady, who has successfully managed a Hepatocellular Carcinoma (HCC) with a transarterial chemoembolization (TACE) performed at a hospital in Romania, Cluj.
My purpose in sharing this with you is to create positive reference points for you. To see and believe that tumors can be destroyed regardless of their type and stage. There are different solutions for that and TACE is one such solution.
Although I did not had the chance to allocate a specific article to TACE, we have often discussed TACE as a good tool to locally address tumors. Nearly 3 years ago, I mentioned TACE as one of the most effective solutions in my view, to address tumors locally https://www.cancertreatmentsresearch.com/some-of-the-most-effective-treatments-in-my-view/. This can be a great tool to address tumors (primary or metastasis) located at the liver and lungs. I heard of doctors open to even perform such intervention for brain tumors. It can be given with embolization or regionally by releasing chemo into a region of the body without embolization (when more tumors need to be addressed at the same time). The major advantage is that higher dose can be given at a specific location, while the dose is small enough from a systemic point of view so that there are much much less side effects compared to the typical IV (systemic) administration of chemo. The disadvantage is that tumors can only be addressed locally and not in the whole body at the same time. And the price may be high (about 5000USD) if this is not covered by insurance. But still accessible for many. And again, its a great tool to address locally tumors, specifically the large ones. For those who would like to know more about TACE, here is a short summary of that, but you can also address questions via the comments field located at the bottom of this page.
Back, to the case report I would like to share with you here, Stefan has kindly asked his sister in law to consolidate her treatment history and related results, and shared that with be so that in turn I can share it with you.
Its a pleasure for me to be able to share this successful results, and I promise there are more great case reports that will be coming soon.
I got the latest information from the sister, but I understand it.
Woman, 74 years old.
2008 – Diagnostic-Hepatic Cirrhosis.
03.2014 – alpha feto protein (AFP)-4.53
03.2015 – AFP-118.
10.2015 – Diagnostic-hepatocarcinoma 21 / 9mm
11.2015 – AFP-400 Performed radiofrequency ablation
02.2016 – AFP 4.59
03.2016 – diagnostic-hepatocarcinoma in segment 6-7
12.2016 – AFP-300
02.2017 – AFP-1366
02.2017 – chemotherapy with nexavar begins
04.2017 – a 35 mm nodular structure appears on the ultrasound
05.2017 – stops chemo for 7 days for platelet recovery as it decreased to less than 62. Restarts chemo for a week after which it is definitively discontinued. During the chemo period, cachexia manifested itself very aggressively and in all its forms, with drastic effects on the body. Weight recovery was very slow and long
06.2017 – radiofrequency ablation without positive effects
06.2017 – CT-to lung, 11mm star-node. From 06.017 to 12.2017, AFP evolved from 2015 to 14357
01.2018 – PET-CT confirms 55/28 mm hipodense liver tumors, bilobate and non-homogeneous FDG (suv max. 7.5). Subsequently, in the neighboring segment 7 inferolateral, a 15 mm cyst without FDG capture is distinguished. FDG capture form (max. 6) of 40/20 mm diameter, located endoluminal to the check level. The lungs, bilaterally expanding, present in LSD segment 2, a 6 mm node, not sufficiently characterizing PET. PET Conclusions: liver tumor, metabolic activity is maintained; active metabolic cecal node; biopsy and endoscopic assessment
02.2018 – Endoscopy
02.2018 – AFP 23000
04.2018 – programming for TACE (Oncology Hospital in Cluj, Romania) on 12.06
12.06.2018 – AFP over 30000
12.06.2018 -TACE with 75 mg doxorubicin, including 5-10 ml gelaspon
05.07.2018 – AFP dropped to 2000
20.07.2018 – CT indicates – embolized node was reduced from 60 to 40 mm. The 2015 ablation scar was diminished. Dimensionally reduced also the nodule near the diaphragm
08.09.2018 – AFP 4.8 at 2 months from TACE
20.09.2018 – MRI with Primovist contrast substance. Cirrhosis-shaped liver with irregular capsular contours. Segment 7 reveals two necrotic beaches following treatment of HCC nodules at these 35 / 25mm and 28/21mm levels respectively. In segment 3 close to the round ligament crack is shown a small 9 mm hipercaptant node, possibly the dysplastic node (10-11 mm) without dilated bile ducts. Intra and extrahepatic. No thrombosis at the port axis. Spline increased in volume with an axle of about 18 mm. Pancreas, adrenal glands of normal MRI appearance. Without ascites fluid
I wrote here exactly what I received from my sister-in-law.
Good bless you all,
This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, I provide general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. I am not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site. This is just my own personal opinion regarding what we have learned on this road.
Please read an extended version of the Disclaimer here: https://www.cancertreatmentsresearch.com/?page_id=1794